# US 2025/0145691 A1 · Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145691 A1
- Document ID: US20250145691A1
- Status: Published application
- Kind: A1
- Application number: 18/838,785
- Filed: 2023-02-15
- Published: 2025-05-08
- Earliest claimed: 2022-02-15
- Assignees: Board of Regents, The University of Texas System; The University of North Carolina at Chapel Hill
- Applicants: Board of Regents, the University of Texas System; The University of North Carolina At Chapel Hill
- Inventors: Gregory C. IPPOLITO; Jason J. LAVINDER; George GEORGIOU; William N. VOSS; Ralph BARIC
- Web page: https://patentgrep.com/patent/US20250145691A1

## CPC

- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- A61P 31/14: for RNA viruses
- G01N 33/56983: {Viruses}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are antibodies and antibody fragments that bind to the S2 subunit of the SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein S2 subunit-targeting antibody.

## Claims

### Claim 1

A monoclonal antibody or antibody fragment, wherein the antibody or antibody fragment comprises clone-paired heavy and light chain CDR sequences derived from the clone-paired heavy chain and light chain variable sequences of Table 2.

### Claim 2 (depends on 1)

The monoclonal antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment comprises clone-paired heavy and light chain CDR sequences from Table 1.

### Claim 3 (depends on 1)

The monoclonal antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment comprises clone-paired heavy chain and light chain variable sequences having, independently, at least 70%, 80%, or 90% identity to sequences from Table 2.

### Claim 4 (depends on 1)

The monoclonal antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment comprises clone-paired heavy chain and light chain variable sequences each having at least 95% identity to sequences from Table 2.

### Claim 5 (depends on 1)

The monoclonal antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment comprises clone-paired heavy chain and light chain variable sequences from Table 2.

### Claim 6 (depends on 1)

The monoclonal antibody or antibody fragment of claim 1, wherein the antibody fragment is a recombinant scFv (single chain fragment variable) antibody, Fab fragment, F(ab′)2 fragment, or Fv fragment.

### Claim 7 (depends on 1)

The monoclonal antibody or antibody fragment of claim 1, wherein the antibody is a chimeric antibody or a bispecific antibody.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The monoclonal antibody or antibody fragment of any one of claims 1-7, wherein the antibody is capable of binding to SARS-CoV-2 spike protein.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The monoclonal antibody or antibody fragment of any one of claims 1-8, wherein the antibody is an IgG antibody or a recombinant IgG antibody or antibody fragment.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The monoclonal antibody or antibody fragment of any one of claims 1-9, wherein the antibody or antibody fragment is fused to an imaging agent.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The monoclonal antibody or antibody fragment of any one of claims 1-9, wherein the antibody or antibody fragment is labeled.

### Claim 12 (depends on 11)

The monoclonal antibody or antibody fragment of claim 11, wherein the label is a fluorescent label, an enzymatic label, or a radioactive label.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A monoclonal antibody or antibody fragment, which competes for binding to the same epitope as the monoclonal antibody or an antibody fragment according to any one of claims 1-9.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A monoclonal antibody or antibody fragment that binds to an epitope on SARS-CoV-2 spike protein recognized by an antibody of any one of claims 1-9.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 13)

An isolated nucleic acid encoding the antibody heavy and/or light chain variable region of the antibody or antibody fragment of any one of claims 1-9, 13, and 14.

### Claim 16 (depends on 15)

An expression vector comprising the nucleic acid of claim 15.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 13)

A hybridoma or engineered cell comprising a nucleic acid encoding an antibody or antibody fragment of any one of claims 1-9, 13, and 14.

### Claim 18 (depends on 15)

A hybridoma or engineered cell comprising a nucleic acid of claim 15.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 17, 18)

A method of making the monoclonal antibody or antibody fragment of any one of claims 1-9, 13, and 14, the method comprising culturing the hybridoma or engineered cell of claim 17 or 18 under conditions that allow expression of the antibody or antibody fragment and optionally isolating the antibody or antibody fragment from the culture.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A pharmaceutical formulation comprising one or more antibody or antibody fragment of any one of claims 1-14.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 13)

A pharmaceutical formulation comprising one or more expression vector encoding a first antibody or antibody fragment of any one of claims 1-9, 13, and 14.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of reducing the likelihood of a SARS-CoV-2 infection in a patient at risk of contracting SARS-CoV-2, the method comprising delivering to the patient an antibody or antibody fragment of any one of claims 1-14.

### Claim 23 (depends on 22)

The method of claim 22, further characterized as a method of preventing a SARS-CoV-2 infection in the patient.

### Claim 24 (depends on 22)

The method of claim 22, wherein the patient has been exposed to SARS-CoV-2.

### Claim 25 (depends on 22)

The method of claim 22, wherein the antibody or antibody fragment is delivered to the patient prior to infection or after infection.

### Claim 26 (depends on 22, 23, 24, 25)

The method of any one of claims 22-25, wherein delivering comprises antibody or antibody fragment administration, or genetic delivery with an RNA or DNA sequence or vector encoding the antibody or antibody fragment.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating a patient infected with SARS-CoV-2, the method comprising delivering to the patient an antibody or antibody fragment of any one of claims 1-14.

### Claim 28 (depends on 27)

The method of claim 27, wherein delivering comprises antibody or antibody fragment administration, or genetic delivery with an RNA or DNA sequence or vector encoding the antibody or antibody fragment.

### Claim 29 (depends on 27, 28)

The method of claim 27 or 28, wherein the method reduces the viral load in the patient.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of detecting a SARS-CoV-2 infection in a patient, the method comprising:
(a) contacting a sample obtained from the patient with an antibody or antibody fragment of any one of claims 1-14; and
(b) detecting SARS-CoV-2 in the sample by detecting binding of the antibody or antibody fragment to a SARS-CoV-2 antigen in the sample.

### Claim 31 (depends on 30)

The method of claim 30, wherein the sample is a body fluid.

### Claim 32 (depends on 30, 31)

The method of claim 30 or 31, wherein said sample is blood, sputum, tears, saliva, mucous or serum, semen, cervical or vaginal secretions, amniotic fluid, placental tissues, urine, exudate, transudate, tissue scrapings or feces.

### Claim 33 (depends on 30, 31, 32)

The method of any one of claims 30-32, wherein detecting comprises an ELISA, RIA, lateral flow assay or Western blot.

### Claim 34 (depends on 30, 31, 32, 33)

The method of any one of claims 30-33, further comprising performing steps (a) and (b) a second time and determining a change in SARS-CoV-2 antigen levels as compared to the first assay.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of determining an antigenic integrity, correct conformation and/or correct sequence of a SARS-CoV-2 antigen, the method comprising:
(a) contacting a sample comprising the antigen with a first antibody or antibody fragment of any one of claims 1-14; and
(b) determining antigenic integrity, correct conformation and/or correct sequence of the antigen by detecting binding of the first antibody or antibody fragment to the antigen.

### Claim 36 (depends on 35)

The method of claim 35, wherein the sample comprises a recombinantly produced antigen.

### Claim 37 (depends on 35)

The method of claim 35, wherein the sample comprises a vaccine formulation comprising the antigen.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein detecting comprises an ELISA, RIA, lateral flow assay or Western blot.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35-38, further comprising performing steps (a) and (b) a second time to determine the antigenic stability of the antigen over time.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of detecting SARS-CoV-2 spike protein in an in vitro sample, the method comprising contacting the in vitro sample with an antibody or antibody fragment of any one of claims 1-14 and detecting the binding of the antibody or antibody fragment to the sample.

### Claim 41 (depends on 40)

The method of claim 40, wherein the detecting is by flow cytometry, mass spectrometry, western blot, immunohistochemistry, ELISA, or RIA.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 20, 21)

An antibody or antibody fragment of any of claims 1-14 or a pharmaceutical formulation of claim 20 or 21, for use in treating or preventing a SARS-CoV-2 infection in a patient.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 20, 21)

Use of an antibody or antibody fragment of any of claims 1-14 or a pharmaceutical formulation of claim 20 or 21, in the manufacture of a medicament for treating or preventing a SARS-CoV-2 infection in a patient.
